Candel Therapeutics, Inc.
CADL
$4.76
$0.224.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 2,339.47% | -86.67% | |||
| Gross Profit | -2,339.47% | 86.67% | |||
| SG&A Expenses | -6.31% | -6.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.50% | 2.17% | |||
| Operating Income | 15.50% | -2.17% | |||
| Income Before Tax | -32.19% | 52.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.19% | 52.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.19% | 52.12% | |||
| EBIT | 15.50% | -2.17% | |||
| EBITDA | 15.94% | -2.28% | |||
| EPS Basic | -19.01% | 55.33% | |||
| Normalized Basic EPS | -12.75% | 55.33% | |||
| EPS Diluted | -19.01% | 55.33% | |||
| Normalized Diluted EPS | -12.75% | 55.33% | |||
| Average Basic Shares Outstanding | 11.09% | 7.15% | |||
| Average Diluted Shares Outstanding | 11.09% | 7.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||